Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non‐Diabetic Adults: A Meta‐Analysis of Randomised Controlled Trials
Pooled result · Percentage body weightResult — go to the resultMD −12.42 % 95% CI −16.15% to −8.68%Authors' conclusion
Mazdutide effectively reduces weight, waist circumference and blood pressure but may cause mild to moderate adverse events. Findings are limited by the small number of RCTs.
Study context
- Population
- Non-diabetic adults (≥ 18 years) with overweight or obesity5 randomised controlled trials (RCTs)
- Comparison
- Mazdutide vs comparator
- Outcome
- Percentage body weight
Methodological detailsrandom-effect models
- Random-effect models
Pooled result
As reported in the abstract
MD
−12.42 %
95% CI −16.15% to −8.68%
Mazdutidevs comparator
MD −12.42 % (95% CI −16.15% to −8.68%)
Further pooled results
Absolute body weight
| MD (kg) (95% CI) | ||
|---|---|---|
| Mazdutide | −9.76 (−13.15 to −6.37) | |
| −20−10010Difference, kg (linear scale) |
Waist circumference
| MD (cm) (95% CI) | ||
|---|---|---|
| Mazdutide | −7.98 (−10.24 to −5.72) | |
| −15−10−505Difference, cm (linear scale) |
Systolic blood pressure
- Systolic blood pressure decreased, MD
- −7.68 mmHg
Total cholesterol
- Total cholesterol decreased, MD
- −0.57 mmol/L
LDL
- LDL decreased, MD
- −0.37 mmol/L
Dose-wise meta-regression
- Significant dose-wise effects, β
- −0.99 (95% CI −1.81 to −0.16; p = 0.0187)
Safety
- Adverse events slightly increased, RR
- 1.12
Original publication
Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non‐Diabetic Adults: A Meta‐Analysis of Randomised Controlled Trials. Diabetes Obes Metab. Published 10 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →